Document Detail

The current status of engineering myocardial tissue.
MedLine Citation:
PMID:  20198517     Owner:  NLM     Status:  In-Data-Review    
Myocardial infarction (MI) remains a common fatal disease all over the world. The adult cardiac myocytes regenerative capability is very limited after infarct injury. Heart transplantation would be the best therapeutic option currently but is restricted due to the lack of donor organs and the serious side effects of immune suppression. The emerging of tissue engineering has evolved to provide solutions to tissue repair and replacement. Engineering myocardial tissue is considered to be a new therapeutic approach to repair infarcted myocardium and ameliorate cardiac function after MI. Engineering myocardial tissue is the combination of biodegradable scaffolds with viable cells and has made much progress in the experimental phase. However, the largest challenge of this field is the revascularization of the engineering constructs to provide oxygen and nutrients for cells. This review will give an overview on the current evolution of engineering myocardial tissue and address a new method to improve the vascularization of myocardium tissue in vivo.
Runqian Sui; Xiaobo Liao; Xinmin Zhou; Qi Tan
Related Documents :
18054407 - Fibroblast growth factors and hedgehogs: at the heart of the epicardial signaling center.
17336907 - Notch signaling is essential for ventricular chamber development.
21063047 - Clinical applications of stem cell therapy for regenerating the heart.
8006257 - Myocyte nuclear and possible cellular hyperplasia contribute to ventricular remodeling ...
6968257 - Predictors of clinical course, coronary anatomy and left ventricular function after rec...
23349187 - Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Stem cell reviews     Volume:  7     ISSN:  1558-6804     ISO Abbreviation:  Stem Cell Rev     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-01-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101255952     Medline TA:  Stem Cell Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  172-80     Citation Subset:  IM    
Department of Cardiothoracic Surgery, Xiangya Second Hospital, Central South University, Changsha, Hunan, 410011, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stem Cell Research in the Greater Middle East: The Importance of Establishing Policy and Ethics Inte...
Next Document:  Human bone marrow mesenchymal stem cells: a systematic reappraisal via the genostem experience.